Rosuvastatin calcium. Market analysis

Nature Reviews Drug Discovery

Volumn 2, Issue 10, 2003, Pages 769-770

  Quirk, Jeremy ^a   Thornton, Mark ^a   Kirkpatrick, Peter ^b  

^a Decision Resources Intl   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; EZETIMIBE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN; CHOLESTEROL; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ARTICLE; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DYSLIPIDEMIA; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROTEINURIA; RHABDOMYOLYSIS; UNITED STATES; BLOOD; CHEMISTRY;

CHOLESTEROL; DRUG APPROVAL; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PYRIMIDINES; SULFONAMIDES;

EID: 0242300219     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1205     Document Type: Article

References (8)

1. Tobert, J. A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nature Rev. Drug Discov. 2, 517-526 (2003).
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo controlled trial. Lancet 360, 7-22 (2002).
3. Sever, P. S. for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149-1158 (2003).
4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421 (2002).
5. Watanabe, M. et al. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptonates, a novel series of HMG-CoA reductase inhibitors. Bioorg. Med. Chem. 5, 437-444 (1997).
6. FDA Drug Approvals List [online] (cited 26 Aug 2003). http://www.fda.gov/cder/foi/label/2003/21366_crestor_Ibl.pdf (2003).
7. Jones, P. H. et al. for the STELLAR study group. Statin therapies for elevated lipid levels compared across dose ranges to rosuvastatin: low-density lipoprotein cholesterol and high density lipoprotein cholesterol results. J. Am. Coll. Cardiol. 92, 152-160 (2003).
8. Earl, J. & Kirkpatrick, P. Ezetimibe. Nature Rev Drug Discov. 2, 97-98 (2003).